Pfizer, GSK, AbbVie amongst pharmas set to rise in May possibly

With the initial investing day in Could coming on Monday, quite a few pharmaceutical firms will be hoping their returns fare better than they did in April.

The iShares U.S. Pharmaceuticals ETF (IHE) returned a paltry 1.6% in April. The ETF’s prime two holdings are Johnson & Johnson (NYSE:JNJ) and Merck (NYSE:MRK), which account for, respectively, 23.6% and 20.7% of the fund.

The best doing US big pharma or biotech in the month was Eli Lilly (LLY), turning in an impressive 11.3% return. Inspite of a Q1 2023 base line miss, the pharma was buoyed by pounds reduction data for its diabetes drug Mounjaro (tirzepatide).

AbbVie (NYSE:ABBV) was the worst performer with a -7.2% return. It was negatively impacted by disappointing Q1 final results.

Many companies that would like to neglect April have a probability to redeem on their own in May perhaps as there are big occasions, these types of as US Food and drug administration action dates on drug or biologic purposes, that could give a share price tag enhance.

May well 3 could carry a smile to the faces of GlaxoSmithKline (GSK) management and stockholders as that is the date the Food and drug administration is slated to render a final decision on its respiratory syncytial virus (RSV) vaccine Arexvy. In March, a panel of Fda advisors unanimously encouraged its acceptance.

SVB Securities analyst Geoffrey Porges has previously mentioned the RSV vaccine market place could arrive at $10B by 2030.

Pfizer (NYSE:PFE) will also listen to from the Food and drug administration in May perhaps about its very own RSV shot, Abrysvo. Company advisors also suggested Abrysvo. Both of those Pfizer (PFE) and GSK (GSK) are gearing up to start the jabs prior to the conclude of the yr.

Eyenovia (EYEN) is expecting a determination on Could 8 on its resubmitted New Drug Application for MydCombi ophthalmic spray for mydriasis. The pursuing working day, a selection is envisioned for Protalix Biotherapeutics’ (PLX) resubmitted Biologics License Application for pegunigalsidase alfa for Fabry disease.

An Food and drug administration advisory committee will fulfill May perhaps 12 to discuss Sarepta Therapeutics’ (SRPT) BLA for SRP-9001 for Duchenne muscular dystrophy. The motion date is May well 29. Sarepta (SRPT) stock was hit earlier this month right after a report that some Fda workers opposed the gene remedy.

On May perhaps 19, the Food and drug administration is expected to act on Krystal Biotech’s (KRYS) B-VEC for dystrophic epidermolysis bullosa. A determination is expected the similar working day on an NDA for obeticholic acid as a remedy for pre-cirrhotic liver fibrosis because of to nonalcoholic steatohepatitis from Intercept Prescribed drugs (ICPT).

AbbVie (ABBV) will find out on May possibly 21 the destiny of its epcoritamab BLA for relapsed/refractory substantial B-mobile lymphoma. The corporation is partnered with Genmab (GMAB) on the prospect.

An Fda choice on an additional sign for Blueprint Medicine’s (BPMC) Ayvakit (avapritinib) for indolent systemic mastocytosis is predicted May perhaps 22. The subsequent day, a choice of ImmunityBio’s (IBRX) Anktiva (N-803) for BCG-unresponsive non-muscle mass-invasive bladder most cancers carcinoma is planned.

The final catalyst of May possibly is possible on Could 29 with a final decision on Innoviva’s (INVA) sulbactam-durlobactam for the cure of healthcare facility-obtained bacterial pneumonia and ventilator-linked bacterial pneumonia.

Sometime through the month, the Food and drug administration is slated to act on Lexicon Pharmaceuticals’ (LXRX) sotagliflozin for coronary heart failure.